Tools

Which psychedelic therapy might fit you?

A short, client-side decision tree that takes your goals, medical considerations, and legal constraints and suggests which therapy the evidence and access landscape supports exploring first. Not medical advice.

Depression treatment path

A practical next-step guide for treatment-resistant depression: compare Spravato, IV/IM ketamine, at-home ketamine, psilocybin trials, and Oregon/Colorado psilocybin services by legality, insurance, evidence, and what to ask at the first appointment.

At-home ketamine safety checklist

A safety-first guide to what is actually available at home: compounded oral/sublingual ketamine via telehealth, why Spravato is never take-home, what remote integration can and cannot do, and when at-home treatment is the wrong starting point.

Find a ketamine therapy provider

Curated directory of US ketamine therapy providers — at-home telehealth programs, in-clinic IV/IM infusion networks, and the Spravato (esketamine) REMS network — with vetting guidance.

Find a psychedelic-integration therapist

A curated meta-directory of the established psychedelic-therapist training programs (Fluence, CIIS, Polaris, IPI, Naropa, Sage, MAPS) whose alumni directories are the credible starting points.

Find a legal psychedelic retreat

Oregon Measure 109 and Colorado Prop 122 licensed service centers, plus the more medically-structured international operators for ayahuasca, ibogaine, and 5-MeO-DMT. Includes a retreat vetting checklist.

Legal psilocybin booking checklist

Step-by-step checklist for booking legal psilocybin services: verify Oregon or Colorado licenses, distinguish legal service centers from decriminalized possession, estimate total cost, screen facilitators, and plan preparation and integration.

Psychedelic Legalization Tracker

A running, auto-updated log of psychedelic legalization moves — new laws, decriminalizations, reschedulings, trial funding, and court rulings across US states and other countries, each linked to its source.

Psychedelic legal status by US state

Plain-English reference for where each state stands on therapeutic access, decriminalization, and active legislation. Filterable by reform type.

Psychedelic Legal Status Map of the United States

National overview of where every US state stands on psilocybin, MDMA, DMT, ibogaine, and ketamine. Four-tier ranking, clickable state grid, and 2026 reform watchlist.

Find Psychedelic Clinical Trials: How to Volunteer

How to find and apply for psychedelic clinical trials: psilocybin, MDMA, ibogaine, DMT, and ketamine. Registry links, institution-specific portals, eligibility criteria, what participation involves, and how participants are protected.

Ceremony readiness quiz

A 12-question self-assessment that scores your readiness for a psychedelic ceremony across medical, psychological, logistical, and integration dimensions. Not a clearance, not medical advice.

Trauma trigger to healing map

Pick a common trigger (criticism, abandonment, conflict, shame) and see the four F's response it usually maps to, what wound it points to, and the integration practices that support healing.

Psychedelic retreat cost calculator

Add your retreat quote to travel, extra nights, insurance, screening, integration sessions and unpaid time off to see the all-in cost of the trip. Runs in your browser; nothing is saved.

Questions to ask before psychedelic therapy

Pick your route (Spravato, ketamine clinic, at-home ketamine, a licensed psilocybin service, a trial or a retreat) and who you are asking, and get a printable list of questions from our checklists.

Psychedelic medication safety checker

An interactive screener: enter your prescriptions and supplements and see typical clinical-trial washout windows and the high-risk combinations. Educational only — always coordinate with your prescriber.

Cost-Effectiveness of Ketamine vs. ECT in US Depression Care

A 2026 cost-effectiveness analysis compares ketamine and ECT for nonpsychotic treatment-resistant depression, weighing costs and QALYs. The findings may influence clinical guidelines, reimbursement, and patient access in the US.

Oct 22, 2026

CBP Delays De Minimis Exemption Suspension: Implications for Psychedelic Imports

CBP's extension of the de minimis exemption suspension delays stricter controls on small-value mail imports, affecting psychedelic research and unregulated substance sourcing. Stakeholders should prepare for future enforcement and evolving compliance requirements.

Oct 22, 2026

Low-Dose Ketamine for Depression: Clinical Evidence and Policy in 2026

A new meta-analysis published in October 2026 confirms moderate, rapid-acting efficacy of low-dose ketamine for treatment-resistant depression. The findings support cautious clinical use, highlight monitoring needs, and may influence future guidelines and regulatory decisions.

Oct 21, 2026

Expectation Bias in Psychedelic Trials: Implications for Research Validity

A new study finds that willingness to join psychedelic clinical trials is shaped by participants' expectations and personality traits, highlighting a selection bias that may skew efficacy estimates and limit generalizability.

Oct 21, 2026

Psilocybin Reduces Inflammation in Parkinson’s: U.S. Phase 2 Data

A new phase 2 trial finds psilocybin reduces inflammation in Parkinson’s disease, suggesting a possible disease-modifying role. This insight could shift research and regulatory focus toward psychedelics’ neuroprotective potential, but key risks and unknowns remain.

Oct 21, 2026